Please enable JavaScript to continue using this application.

Compare $NBP vs $VYGR | Chartloom

Compare

$NBP vs $VYGR

NovaBridge Biosciences · Voyager Therapeutics Inc

NBP

NovaBridge Biosciences

VYGR

Voyager Therapeutics Inc

Compare $NBP vs $VYGR

Comparing NovaBridge Biosciences and Voyager Therapeutics Inc

NBPNovaBridge Biosciences

VYGRVoyager Therapeutics Inc

NBPNovaBridge Biosciences

Market cap

$161M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-67.3%

52W performance

-72.5%

FCF yield

-33.9%

VYGRVoyager Therapeutics Inc

Market cap

$148M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.33x

Rev growth (TTM)

-19.1%

YTD performance

-39.2%

52W performance

-53.6%

FCF yield

-82.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NBP

VYGR

Detailed metrics comparison

NBP

NovaBridge Biosciences

VYGR

Voyager Therapeutics Inc

Market Cap

NBP$161M

VYGR$148M

Enterprise Value

NBP$-30M

VYGR$112M

Price

NBP$1.40

VYGR$2.45

P/E Ratio

NBPN/A

VYGRN/A

P/S Ratio

NBP3.29x

VYGR4.30x

EV/Sales

NBP0.00x

VYGR3.26x

EV/EBITDA

NBP0.00x

VYGR8.61x

P/B Ratio

NBP0.77x

VYGR1.01x

P/FCF Ratio

NBPN/A

VYGRN/A

EV/FCF

NBP0.55x

VYGR-0.92x

PEG Ratio

NBPN/A

VYGRN/A

Forward P/E (NTM)

NBPN/A

VYGRN/A

Forward P/S (NTM)

NBPN/A

VYGR5.33x

Revenue (TTM)

NBP$0

VYGR$34M

Revenue Growth (YoY)

NBPN/A

VYGR-19.1%

Forward Rev Growth

NBP419.8%

VYGR129.7%

Gross Margin (TTM)

NBP100.0%

VYGR0.0%

Operating Margin (TTM)

NBP0.0%

VYGR0.0%

EBITDA Margin (TTM)

NBP0.0%

VYGR-329.0%

Net Margin (TTM)

NBP0.0%

VYGR-312.6%

FCF Margin (TTM)

NBPN/A

VYGR-352.4%

Net Income (TTM)

NBP$-43M

VYGR$-108M

FCF (TTM)

NBP$-55M

VYGR$-121M

EPS (TTM)

NBP$0.00

VYGR-$1.78

ROE (TTM)

NBP-2091.0%

VYGR-5792.0%

ROA (TTM)

NBP-1941.0%

VYGR-4500.0%

ROIC (TTM)

NBP-2091.0%

VYGR-5792.0%

Cash

NBP$191M

VYGR$36M

Debt

NBP$0

VYGR$0

Net Cash/Debt

NBP$191M

VYGR$36M

Current Ratio (TTM)

NBP7.64x

VYGR7.51x

Quick Ratio (TTM)

NBP7.60x

VYGR7.16x

Debt/Equity (TTM)

NBP0.00x

VYGR0.00x

Debt/Assets (TTM)

NBP0.0%

VYGR0.0%

Interest Coverage (TTM)

NBPN/A

VYGRN/A

Net Debt/EBITDA (TTM)

NBP0.00x

VYGR0.00x

Beta

NBP1.69

VYGR1.11

52W Performance

NBP-72.5%

VYGR-53.6%

YTD Performance

NBP-67.3%

VYGR-39.2%

% from 52W High

NBP-79.5%

VYGR-55.9%

% from 52W Low

NBP6.5%

VYGR5.2%

Asset Turnover (TTM)

NBP0.11x

VYGR0.14x

FCF Yield (TTM)

NBP-33.9%

VYGR-82.0%

Earnings Yield (TTM)

NBP-26.8%

VYGR-72.8%

Dividend Yield (TTM)

NBPN/A

VYGRN/A

Rule of 40

NBP0.0

VYGR-371.4

EV/GP/RG

NBPN/A

VYGRN/A

Ticker research

View NBP research View VYGR research

Metric	NBP NovaBridge Biosciences	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$161M	$148M
Enterprise Value	$-30M	$112M
Price	$1.40	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.29x	4.30x
EV/Sales	0.00x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.77x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	0.55x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$0	$34M
Revenue Growth (YoY)	N/A	-19.1%
Forward Rev Growth	419.8%	129.7%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-329.0%
Net Margin (TTM)	0.0%	-312.6%
FCF Margin (TTM)	N/A	-352.4%
Net Income (TTM)	$-43M	$-108M
FCF (TTM)	$-55M	$-121M
EPS (TTM)	$0.00	-$1.78
ROE (TTM)	-2091.0%	-5792.0%
ROA (TTM)	-1941.0%	-4500.0%
ROIC (TTM)	-2091.0%	-5792.0%
Financial Health
Cash	$191M	$36M
Debt	$0	$0
Net Cash/Debt	$191M	$36M
Current Ratio (TTM)	7.64x	7.51x
Quick Ratio (TTM)	7.60x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.69	1.11
52W Performance	-72.5%	-53.6%
YTD Performance	-67.3%	-39.2%
% from 52W High	-79.5%	-55.9%
% from 52W Low	6.5%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.14x
FCF Yield (TTM)	-33.9%	-82.0%
Earnings Yield (TTM)	-26.8%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View NBP research	View VYGR research

Valuation

P/S Ratio

NBP

3.29x

VYGR

4.30x

EV/FCF

VYGR

-0.92x

NBP

0.55x

Growth & revenue

Revenue Growth TTM

VYGR

-19.1%

Forward Revenue Growth

NBP

419.8%

VYGR

129.7%

Profitability & performance

Gross Margin

NBP

100.0%

VYGR

0.0%

ROE

NBP

-2091.0%

VYGR

-5792.0%

FCF Yield %

NBP

-33.9%

VYGR

-82.0%

52-Week Performance

VYGR

-53.6%

NBP

-72.5%

Detailed metrics comparison

NBP

NovaBridge Biosciences

VYGR

Voyager Therapeutics Inc

Market Cap

NBP$161M

VYGR$148M

Enterprise Value

NBP$-30M

VYGR$112M

Price

NBP$1.40

VYGR$2.45

P/E Ratio

NBPN/A

VYGRN/A

P/S Ratio

NBP3.29x

VYGR4.30x

EV/Sales

NBP0.00x

VYGR3.26x

EV/EBITDA

NBP0.00x

VYGR8.61x

P/B Ratio

NBP0.77x

VYGR1.01x

P/FCF Ratio

NBPN/A

VYGRN/A

EV/FCF

NBP0.55x

VYGR-0.92x

PEG Ratio

NBPN/A

VYGRN/A

Forward P/E (NTM)

NBPN/A

VYGRN/A

Forward P/S (NTM)

NBPN/A

VYGR5.33x

Revenue (TTM)

NBP$0

VYGR$34M

Revenue Growth (YoY)

NBPN/A

VYGR-19.1%

Forward Rev Growth

NBP419.8%

VYGR129.7%

Gross Margin (TTM)

NBP100.0%

VYGR0.0%

Operating Margin (TTM)

NBP0.0%

VYGR0.0%

EBITDA Margin (TTM)

NBP0.0%

VYGR-329.0%

Net Margin (TTM)

NBP0.0%

VYGR-312.6%

FCF Margin (TTM)

NBPN/A

VYGR-352.4%

Net Income (TTM)

NBP$-43M

VYGR$-108M

FCF (TTM)

NBP$-55M

VYGR$-121M

EPS (TTM)

NBP$0.00

VYGR-$1.78

ROE (TTM)

NBP-2091.0%

VYGR-5792.0%

ROA (TTM)

NBP-1941.0%

VYGR-4500.0%

ROIC (TTM)

NBP-2091.0%

VYGR-5792.0%

Cash

NBP$191M

VYGR$36M

Debt

NBP$0

VYGR$0

Net Cash/Debt

NBP$191M

VYGR$36M

Current Ratio (TTM)

NBP7.64x

VYGR7.51x

Quick Ratio (TTM)

NBP7.60x

VYGR7.16x

Debt/Equity (TTM)

NBP0.00x

VYGR0.00x

Debt/Assets (TTM)

NBP0.0%

VYGR0.0%

Interest Coverage (TTM)

NBPN/A

VYGRN/A

Net Debt/EBITDA (TTM)

NBP0.00x

VYGR0.00x

Beta

NBP1.69

VYGR1.11

52W Performance

NBP-72.5%

VYGR-53.6%

YTD Performance

NBP-67.3%

VYGR-39.2%

% from 52W High

NBP-79.5%

VYGR-55.9%

% from 52W Low

NBP6.5%

VYGR5.2%

Asset Turnover (TTM)

NBP0.11x

VYGR0.14x

FCF Yield (TTM)

NBP-33.9%

VYGR-82.0%

Earnings Yield (TTM)

NBP-26.8%

VYGR-72.8%

Dividend Yield (TTM)

NBPN/A

VYGRN/A

Rule of 40

NBP0.0

VYGR-371.4

EV/GP/RG

NBPN/A

VYGRN/A

Ticker research

View NBP research View VYGR research

Metric	NBP NovaBridge Biosciences	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$161M	$148M
Enterprise Value	$-30M	$112M
Price	$1.40	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	3.29x	4.30x
EV/Sales	0.00x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.77x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	0.55x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$0	$34M
Revenue Growth (YoY)	N/A	-19.1%
Forward Rev Growth	419.8%	129.7%
Profitability
Gross Margin (TTM)	100.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-329.0%
Net Margin (TTM)	0.0%	-312.6%
FCF Margin (TTM)	N/A	-352.4%
Net Income (TTM)	$-43M	$-108M
FCF (TTM)	$-55M	$-121M
EPS (TTM)	$0.00	-$1.78
ROE (TTM)	-2091.0%	-5792.0%
ROA (TTM)	-1941.0%	-4500.0%
ROIC (TTM)	-2091.0%	-5792.0%
Financial Health
Cash	$191M	$36M
Debt	$0	$0
Net Cash/Debt	$191M	$36M
Current Ratio (TTM)	7.64x	7.51x
Quick Ratio (TTM)	7.60x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.69	1.11
52W Performance	-72.5%	-53.6%
YTD Performance	-67.3%	-39.2%
% from 52W High	-79.5%	-55.9%
% from 52W Low	6.5%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.14x
FCF Yield (TTM)	-33.9%	-82.0%
Earnings Yield (TTM)	-26.8%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View NBP research	View VYGR research